PFE  Pfizer Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

205.72B

Vuru Grade

60.55/100

Current Price

$33.92
+0.085 (+0.251%)

Growth Price

$25.70
Overvalued by 24.23%

Stability Price

$11.98
Overvalued by 64.67%

Company Metrics

  • P/E 30.066
  • P/S 3.925
  • P/B 3.27
  • EPS 1.128
  • Cash ROIC 13.13%
  • Cash Ratio 0.79
  • Dividend 1.2 / 3.5%
  • Avg. Vol. 19.32M
  • Shares 6.07B
  • Market Cap. 205.72B

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Pfizer decides against split-up; more deals seen likely
Reuters - Sep 26, 2016
NEW YORK Pfizer Inc (PFE.N), which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines.
Will Pfizer Inc.'s (PFE) Non-Split Policy be Beneficial for the Company? - TCC
Pfizer Throws Out Plan to Split Into Two Companies - Wall Street Journal
You Can't Ignore This News on Pfizer Inc. (PFE) Stock
Income Investors - Sep 27, 2016
Pfizer Inc. (NYSE:PFE) has finally decided what investors wanted to hear. The world's second-largest pharmaceutical company has given up the idea to split its business, ending years of uncertainty and speculations which had surrounded PFE stock.
Analysts: Pfizer Inc. (NYSE:PFE) stock is worth $39.47 - Review Fortune
Pfizer Inc. (PFE) Sees Unusually-High Trading Volume Following Dividend ... - The Cerbat Gem
Better Buy: Pfizer Inc. vs. AbbVie Inc.
Motley Fool - Sep 15, 2016
If it sounds like Pfizer is trying to buy its way to growth, it's because that's exactly what the company is attempting to do.
Pfizer Inc. (PFE) Given "Buy" Rating at Bank of America Corp.
The Cerbat Gem - 15 hours ago
Pfizer Inc. logo Bank of America Corp. reaffirmed their buy rating on shares of Pfizer Inc. (NYSE:PFE) in a research note released on Tuesday morning.
What Pfizer Inc. (NYSE:PFE) Licensing Deal With OncoImmune, Inc. Means For ... - Market Exclusive
Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of "Buy" from Analysts - Community Financial News
Pfizer: No Buy Signal After The Dip
Seeking Alpha - 9 hours ago
Pfizer is down sharply over the last couple of months culminating with a decision to not split into two companies. The company has a stock buyback plan, but chooses to use larger amounts of cash on making acquisitions such as paying $14 billion for ...
Plan by Pfizer to Split Into Two Companies Abandoned - CDA News
Pfizer's 9% Decline Gives Dividend Investors Buying Opportunity
Seeking Alpha - Sep 27, 2016
Pfizer stock has taken a dip since the company announced it would not break itself up, preferring instead to remain a single entity.
Pfizer (PFE) Closes Medivation (MDVN) Acquisition
StreetInsider.com - 16 hours ago
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Medivation, Inc.(NASDAQ: MDVN). As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately ...
Pfizer Inc. (NYSE:PFE) Acquisition Of Medivation, Inc. (NASDAQ:MDVN) To Close ... - Market Exclusive
OncoImmune Announces Option and License Agreement with Pfizer Inc.
Business Wire (press release) - Sep 15, 2016
ROCKVILLE, Md.--(BUSINESS WIRE)--OncoImmune, Inc. today announced that it has entered into an exclusive option and license agreement with Pfizer Inc. (NYSE: PFE) for ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody in a ...
Pfizer Seals License Deal with OncoImmune For Monoclonal Antibody ONC-392 In ... - Post News
Buzz Stocks: Pfizer Inc., GW Pharmaceuticals PLC, and Chemtura Corp
Schaeffers Research (blog) - Sep 26, 2016
The company added that the decision will not impact its full-year financial outlook. Looking at Pfizer Inc.'s chart, the shares have underperformed the S&P 500 Index (SPX) by roughly 7 percentage points during the past two months, trimming their year ...
Analysts showing optimistic trends for: Pfizer Incorporated (NYSE:PFE)
News Oracle - Sep 27, 2016
Pfizer Inc. (NYSE:PFE) reported its last earnings on Nov 01 BMO (BMO = before market open, AMC= after market close). The company will report its next earnings on 1-Nov-16.